User: Guest  Login
Title:

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.

Document type:
Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Article
Author(s):
Stüve, O; Cravens, PD; Frohman, EM; Phillips, JT; Remington, GM; von Geldern, G; Cepok, S; Singh, MP; Cohen Tervaert, JW; De Baets, M; MacManus, D; Miller, DH; Radu, EW; Cameron, EM; Monson, NL; Zhang, S; Kim, R; Hemmer, B; Racke, MK
Abstract:
OBJECTIVE: Natalizumab is a humanized recombinant monoclonal antibody against very late activation antigen-4 approved for the treatment of patients with multiple sclerosis (MS). A phase II study failed to demonstrate a difference between natalizumab treatment groups and the placebo group with regard to gadolinium enhancing lesions on MRI 3 months after discontinuation of therapy. The objective of this study was to assess clinical MS disease activity, surrogate disease markers on MRI, immunologic...     »
Journal title abbreviation:
Neurology
Year:
2009
Journal volume:
72
Journal issue:
5
Pages contribution:
396-401
Language:
eng
Fulltext / DOI:
doi:10.1212/01.wnl.0000327341.89587.76
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/18987352
Print-ISSN:
0028-3878
TUM Institution:
Neurologische Klinik und Poliklinik
 BibTeX